Serum soluble ST2 is associated with ER-positive breast cancer

Metastatic Breast Cancer, Version 1.2012

(2017) Robert W. Carlson et al.   Journal of the National Comprehensive Cancer Network

Evaluation of serum concentrations of vascular endothelial growth factor (VEGF) in breast cancer patients

(2013) Diana Hodorowicz-Zaniewska et al.   POLISH JOURNAL OF PATHOLOGY

Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells

(2012) Annett Schmieder et al.   CYTOKINE

Inhibitor of Apoptosis Protein-Like Protein-2 as a Novel Serological Biomarker for Breast Cancer

(2012) Mingjun Xiang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma

(2011) Ivan Jovanovic et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis

(2011) J Gillibert-Duplantier et al.   ONCOGENE

The IL-33/ST2 pathway — A new therapeutic target in cardiovascular disease

(2011) Ashley M. Miller et al.   PHARMACOLOGY & THERAPEUTICS

Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production

(2009) Y.-S. Choi et al.   BLOOD

Nuclear Interleukin-33 Is Generally Expressed in Resting Endothelium but Rapidly Lost upon Angiogenic or Proinflammatory Activation

(2008) Axel M. Küchler et al.   AMERICAN JOURNAL OF PATHOLOGY